Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Mira Pavlovic"'
Autor:
Francine Brinkhuis, Elaine Julian, Hendrika van den Ham, Fabrizio Gianfrate, Valentina Strammiello, Michael Berntgen, Mira Pavlovic, Peter Mol, Jürgen Wasem, Walter Van Dyck, Antonella Cardone, Christian Dierks, Anja Schiel, Renato Bernardini, Oriol Solà-Morales, Jörg Ruof, Wim Goettsch
Publikováno v:
Health Research Policy and Systems, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background The European Regulation on Health Technology Assessment (EU HTA R), effective since January 2022, aims to harmonize and improve the efficiency of common HTA across Member States (MS), with a phased implementation from January 2025
Externí odkaz:
https://doaj.org/article/660c1c179a5f4b32bace34cbb01905ab
Autor:
Elaine Julian, Oriol Solà-Morales, Maria João Garcia, Francine Brinkhuis, Mira Pavlovic, Carlos Martín-Saborido, Robin Doeswijk, Rosa Giuliani, Anne Willemsen, Wim Goettsch, Bernhard Wörmann, Urania Dafni, Heiner C. Bucher, Begoña Pérez-Valderrama, Renato Bernardini, Fabrizio Gianfrate, Carin A. Uyl-de Groot, Jörg Ruof
Publikováno v:
Journal of Market Access & Health Policy, Vol 12, Iss 3, Pp 128-143 (2024)
Background: This work aimed to determine the role and action points for the involvement of medical societies in the European Health Technology Assessment (EU HTA) Methods: An online pre-convention survey was developed addressing four areas related to
Externí odkaz:
https://doaj.org/article/f7baa0ed8a53416196beab87cb2d5619
Autor:
Thomas Desmet, Elaine Julian, Walter Van Dyck, Isabelle Huys, Steven Simoens, Rosa Giuliani, Mondher Toumi, Christian Dierks, Juliana Dierks, Antonella Cardone, Francois Houÿez, Mira Pavlovic, Michael Berntgen, Peter Mol, Anja Schiel, Wim Goettsch, Fabrizio Gianfrate, Stefano Capri, James Ryan, Pierre Ducournau, Oriol Solà-Morales, Jörg Ruof
Publikováno v:
Journal of Market Access & Health Policy, Vol 12, Iss 1, Pp 21-34 (2024)
Objectives: Stakeholder involvement has long been considered a success factor for a joint European health technology assessment (HTA) process, and its relevance is now anchored in the EU HTA Regulation’s (EU HTAR) legislative wording. Therefore, we
Externí odkaz:
https://doaj.org/article/7f514bab01674db19ecb4093613aaea7
Autor:
Lauren Van Haesendonck, Jörg Ruof, Thomas Desmet, Walter Van Dyck, Steven Simoens, Isabelle Huys, Rosa Giuliani, Mondher Toumi, Christian Dierks, Juliana Dierks, Antonella Cardone, Francois Houÿez, Mira Pavlovic, Michael Berntgen, Peter G.M. Mol, Anja Schiel, Wim Goettsch, Fabrizio Gianfrate, Stefano Capri, James Ryan, Pierre Ducournau, Oriol Solà-Morales, Elaine Julian
Publikováno v:
Journal of Market Access & Health Policy, Vol 11, Iss 1 (2023)
ABSTRACTInvolvement of all relevant stakeholders will be of utmost importance for the success of the developing EU HTA harmonization process.A multi-step procedure was applied to develop a survey across stakeholders/collaborators within the EU HTA fr
Externí odkaz:
https://doaj.org/article/b464df9353d045aaaaa896a7a0f4680a
Autor:
Elaine Julian, Mira Pavlovic, Oriol Sola-Morales, Fabrizio Gianfrate, Mondher Toumi, Heiner C. Bucher, Christian Dierks, Wolfgang Greiner, Peter Mol, Jean-François Bergmann, Tomas Salmonson, Ansgar Hebborn, Mathilde Grande, Antonella Cardone, Jörg Ruof
Publikováno v:
Health Economics Review, Vol 12, Iss 1, Pp 1-15 (2022)
Abstract Objectives Key challenges for a joint European Health Technology Assessment (HTA) include consolidated approaches towards the choice of adequate comparator(s), selection of endpoints that are relevant to patients with a given disease, dealin
Externí odkaz:
https://doaj.org/article/49b7e3fc8c3140c6be0c21e052b00350
Autor:
Mira Pavlovic
Publikováno v:
Frontiers in Medicine, Vol 3 (2016)
Clinical endpoints relevant for relative effectiveness assessment (REA) reflect how patients feel, function, or survive. Outcome data requested by Health Technology Assessment (HTA) bodies in Europe to support reimbursement of an anticancer drug are
Externí odkaz:
https://doaj.org/article/d7ce42380c5d4443a51ce14eead1a112
Autor:
Mira Pavlovic, Anna Kapusniak, Valérie Laigle, Chiara Cadeddu, E. Beck, Mondher Toumi, Maarten J. Postma
Publikováno v:
Vaccine, 39(39), 5706-5718. ELSEVIER SCI LTD
Background: Vaccine market access (VMA) pathways across the European Union (EU) and the United Kingdom (UK) are complex, lengthy, and heterogeneous, particularly when compared with pharmaceuticals. The knowledge base to inform recommendations for opt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fe8a4280f378838c9e3b0312d5519a1
https://research.rug.nl/en/publications/2b1e4bc7-9326-48cd-9178-40aa78bce81f
https://research.rug.nl/en/publications/2b1e4bc7-9326-48cd-9178-40aa78bce81f
Autor:
R. Aschoff, Mar Llamas-Velasco, Mourad Lahfa, Mira Pavlovic, Anthony Bewley, Michael Sticherling, Clara De Simone, A. Martorell, Annunziata Dattola
Publikováno v:
Dermatology and Therapy
Introduction There are clear treatment options for mild psoriasis where topical therapies are the mainstay, and for severe psoriasis where systemic therapy (biologic or non-biologic) is necessary. However, there is less clarity in the ‘grey zone’
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b385fa9335706b614461aa33b4a8988
https://pubmed.ncbi.nlm.nih.gov/34510404
https://pubmed.ncbi.nlm.nih.gov/34510404
Autor:
Rima de Sahb, Isabelle Durand-Zaleski, Pascal Bilbault, Claire Le Jeunne, Mira Pavlovic, Claudine Sapède, Jérôme Garnier, Anne-Françoise Gaudin, Stéphane Roze, Olivier Lalaude
Publikováno v:
Therapies. 71:59-67
Resume L’evaluation medicoeconomique estime, pour une technologie de sante donnee, le surcout et le benefice clinique par rapport a une strategie de reference. L’objectif est d’analyser les criteres de mesure de benefice clinique qui fondent le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1451c82a9a93263390f61bdc7a5229dc
https://doi.org/10.1016/j.therap.2015.12.002
https://doi.org/10.1016/j.therap.2015.12.002
Publikováno v:
International Journal of Technology Assessment in Health Care. 30:508-513
Objectives: Clinical endpoints are defined as valid measures of clinical benefit or harm due to treatment, that describe the impact of treatment on how a patient feels, functions, and survives. The choice of endpoints and the manner in which they are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4c79e8e9625b5aa29d46f534a12c577
https://doi.org/10.1017/s0266462314000592
https://doi.org/10.1017/s0266462314000592